Assessment of Risk Factor for Development of Non-Alcoholic Fatty Liver Disease in Type 2 Diabetic Mellitus Patients of Raigarh Chhattisgarh

Dr. Harish Kumar Uraon, Dr. Onkar Kashyap, Dr. Deba Priya rath


Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver diseases.  It is a histological spectrum of disease and includes the simple steatosis and NASH.  NAFLD may progress to cirrhosis, liver failure, and hepatocellular carcinoma. NAFLD is strongly associated to the features of metabolic syndrome. The purpose of this study was to identify the risk factor for development of Non-Alcoholic Fatty Liver Disease in Type 2 diabetic mellitus patients.

Aims & Objective:  To evaluate the various risk factor for development of NAFLD in Type2 diabetes mellitus patients.

Method: This study was done between May 2015 to June 2016 at the Department of Biochemistry, Late Shri Lakhiram Agrawal Memorial Medical College Associated KGH Raigarh CG. All patients attending the Medicine OPD & IPD for their blood pressure, Anthropometry, Biochemical parameters and Ultrasound abdomen was done. The data were analyzed using SPSS version 20. Descriptive statistics, correlation, regression and one way student’s t-test were performed for data analysis.

Results: NAFLD was observed in 52% of patients who had greater BMI (p < 0.001), 94% of hypertension with frequency (p<0.001). Metabolic syndrome was more frequent in those with NAFLD (p = 0.005). The mean levels of Triglyceride, FBS, PPBS, HBA1C, SGOT, ALP, Urea, Creatinine, T. Bilirubin, D. Bilirubin, Triglyceride, HDL, LDL and VLDL were significantly higher in patients with NAFLD than those without NAFLD (p<0.001). The mean value of Creatinine and ALP had significant correlation with age (p<0.01). Urea, Creatinine, SGOT and HDL showed significant correlation with Hb (p<0.01).

Conclusion: There is higher prevalence of all the components of metabolic syndrome in cases of NAFLD. Its early detection will help in modifying the disease course, delaying complications and will also play a major role in preventive cardiology. Almost half of patients with DM2 were found to have NAFLD, and they have more elevated BMI, as well as higher levels of Triglyceride, FBS, PPBS, HBA1C, SGOT, ALP, Urea, Creatinine, T. Bilirubin, D. Bilirubin, Triglyceride, HDL, LDL and VLDL than subjects without NAFLD.



Full Text:



Bellentani S, Marino M. Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8(1):S4-8.

Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3): 734-43.

BRASIL. Ministerio da Saude. Multicenter study about the prevalence of diabetes mellitus in Brazil. Accessed on: 2009 Mar 3.

Wild S, Roglic G, Green A, Scref R, King H. Global prevalence of diabetes. Diabetes Care. 2004;27(5):1047-53.

Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202-19.

Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172(7):899-905.

Wang Y, Zhou M, Lam K, Xu A. Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. Arq Bras EndocrinolMetabol. 2009;53(2):201-12.

Bugianesi E, Bellentani S, Bedogni G, Tiribelli C, Sigliat-Baroni G, Croce LS, et al. Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Ann Hepatol. 2008;7(2):157-60.

Amarapurkar DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, et al. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver disease. Ann Hepatol. 2006;5(1):30-3.

Prashanth M, Ganesh HK, Vimal MV, John M, Bangdar T, Joshi SR, et al. Prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. JAPI 2009;57(3):205-10.

Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA. Liver cirrhosis and diabetes: risk factores, pathophisiology, clinical implications and managment. World J Gastroenterol. 2009;15(3):280-8.

Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes: The Verona Diabetes Study. Diabetes Care. 1999;22(5):756-61.

Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212-8.

Lautämaki R, Borra R, Iozzo P, Komu M, Lehtimaki T, Salmi M, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J PhysiolEnddocrinolMetab. 2006;291(2):E282-90.

Targher G, Bertolini L, Rodella S, Zoppin G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51(3):444-50.

Chew GT, Gan SK, Watts GF. Revisiting the metabolic syndrome. MJA. 2006;185(8):445-9.

International Diabetes Federation 2005. IDF Consensus Worldwide Definition of the Metabolic Syndrome. Accessed on: Mar 23 2009. Available from:

Hamer WO, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. Radiographics. 2006;26(6):1637-53.

Zander R, Lang W, Wolf HU. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. I. Description of the method. ClinChimActa. 1984;136(1):83-93.

Geloneze B, Vasques AC, Stable CF, Pareja JC, Rosado LE, Queiroz EC, et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras EndocrinolMetabol. 2009;53(2):281-7.

McCullough AJ. Update on nonalcoholic fatty liver disease. J ClinGastroenterol. 2002;34(3):255-62.

Marchesini G, Brizi M, Bianchi G, Bianchi G, Bugianesi E, Mc- Cullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999(5);107:450-5.


  • There are currently no refbacks.